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Abstract
Attention-deficit/hyperactivity disorder (ADHD), the single most common neuropsychiatric
disorder with cognitive and behavioral manifestations, often starts in childhood and usually
persists into adolescence and adulthood. Rarely seen alone, ADHD is most commonly complicated by other neuropsychiatric disorders that must be factored into any intervention plan to
optimally address ADHD symptoms. With more than 30 classical Schedule II (CII) stimulant
preparations available for ADHD treatment, only three nonstimulants (atomoxetine and
extended-release formulations of clonidine and guanfacine) have been approved by the United
States Food and Drug Administration (FDA), all of which focus on modulating the noradrenergic system. Given the heterogeneity and complex nature of ADHD in most patients, research
efforts are identifying nonstimulants which modulate pathways beyond the noradrenergic
system. New ADHD medications in clinical development include monoamine reuptake inhibitors, monoamine receptor modulators, and multimodal agents that combine receptor agonist/
antagonist activity (receptor modulation) and monoamine transporter inhibition. Each of these
“pipeline” ADHD medications has a unique chemical structure and differs in its pharmacologic
profile in terms of molecular targets and mechanisms. The clinical role for each of these agents
will need to be explored with regard to their potential to address the heterogeneity of individuals
struggling with ADHD and ADHD-associated comorbidities. This review profiles alternatives
to Schedule II (CII) stimulants that are in clinical stages of development (Phase 2 or 3).
Particular attention is given to viloxazine extended-release, which has completed Phase 3 studies
in children and adolescents with ADHD.

The Challenge of ADHD
As the most common neurodevelopmental disorder of childhood, attention-deficit/hyperactivity
disorder (ADHD) is characterized by inattention, hyperactivity, and impulsivity. ADHD is
associated with an increased risk of academic, social, and family problems, as well as emotional
dysregulation in children and increased risk of substance abuse, motor vehicle/traffic accidents,
and teenage pregnancy in adolescents.1 ADHD that persists into adulthood has been associated
with lower occupational and economic performance, psychiatric comorbidity (eg, depression,
substance abuse, emotional lability, and anxiety disorders), increased rates of marital problems/
divorce, and more negative assessments of self-worth and self-esteem.1 Although ADHD-related
impairments during school and work are generally the primary focus of intervention, ADHD
behaviors at the beginning and end of the day can be just as impairing as well as stressful and
frustrating for affected individuals and their families.1
© The Author(s), 2020. Published by Cambridge
University Press. This is an Open Access article,
distributed under the terms of the Creative
Commons Attribution licence (http://
creativecommons.org/licenses/by/4.0/), which
permits unrestricted re-use, distribution, and
reproduction in any medium, provided the
original work is properly cited.

Comorbidities: the rule, not the exception, in ADHD
ADHD rarely occurs in isolation. In the National Survey of Children’s Health, parents reported
that 64% of children/adolescents with current ADHD had at least one other mental, emotional,
and/or behavioral disorder.2 The most common are behavioral/conduct disorder, anxiety
problems, depression, autism spectrum disorder, and Tourette syndrome.2 The incidence of
psychiatric comorbidity in adults with ADHD reportedly approaches 90%, with anxiety, depression, and substance abuse being the most common.3
Patients with ADHD and significant comorbid mood or anxiety symptoms are frequently
encountered by clinicians. The traditional practice has been to prioritize mood and anxiety
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problems before ADHD symptoms. Recent findings regarding
antidepressant resistance suggest that this approach may need to
be reconsidered.4 The risk of antidepressant resistance was found
to be >2-fold higher in patients with major depression and comorbid ADHD vs major depression alone.4 Concomitant ADHD
treatment was associated with a significantly lower risk of antidepressant resistance, leading to the conclusion that prompt and
regular treatment of ADHD in dual-diagnosis patients may reduce
the risk of antidepressant resistance.4 Because the functional
impairments of ADHD can exacerbate underlying mood disorders, anxiety disorders, and substance abuse, the careful treatment
of ADHD may provide a more favorable environment for effective
treatment of these psychiatric comorbidities.1
Shortcomings of stimulant therapy
While stimulants (ie, methylphenidates, amphetamines) have been
the primary pharmacologic therapy in ADHD for decades, they are
not suitable in many situations, including the 25% to 30% of
patients who do not achieve optimal symptom reduction or do
not tolerate stimulants;5 some patients with comorbidities (eg,
anxiety, depression, and tics) or conditions (eg, sleep disorders,
eating problems) in which stimulant effects are of concern; in
patients requiring 24-hour symptomatic coverage; and in situations
where there is a risk of nonmedical use, drug diversion, or abuse of
these Schedule II (CII) drugs. Because CII drugs have a high
potential for abuse and severe psychological or physical dependence, nonmedical use/diversion of stimulants is not a trivial issue,
particularly in light of data that nearly 60% of college undergraduates with current prescriptions for stimulants reported having
given away or selling their stimulant medication at least once.6 In
children, adverse effects of long-term, continuous stimulant use on
growth trajectories that may modestly reduce adulthood height and
increase weight and body mass index are also cause for concern.7
Nonstimulants currently approved for ADHD by the FDA are
limited to atomoxetine (ATX) and extended-release formulations
of guanfacine (guanfacine-XR) and clonidine (clonidine-XR). Of
these, only ATX is approved for use in adults. This limited scope of
nonstimulant options is likely to expand in the next several years
since several agents are in clinical development and have successfully completed Phase 2 and/or Phase 3 studies. Each candidate is
unique in terms of chemical structure and putative molecular
targets (Figure 1; Table 1). Based on these pharmacologic profiles,
nonstimulants can be broadly classified as (1) monoamine reuptake
(transporter) inhibitors (eg, ATX); (2) receptor modulators
(guanfacine-XR, clonidine-XR); and (3) multimodal agents.
We review clinical characteristics of the marketed and experimental alternatives to CII stimulants that have demonstrated efficacy in double-blind, placebo-controlled Phase 2 or Phase 3 studies.
Pipeline alternatives to CII stimulants include several monoamine
reuptake inhibitors (dasotraline, centanafadine sustained release,
OPC-64005) and multimodal nonstimulants (vortioxetine, viloxazine extended-release), as well as a multimodal stimulant (mazindol controlled release) with lower abuse potential (CIV).
Monoamine Reuptake (Transporter) Inhibitors
Atomoxetine
Atomoxetine (Strattera®, Eli Lilly) is a selective noradrenergic
reuptake inhibitor with high affinity for presynaptic norepinephrine transporters (NET).8,9 Although ATX was first evaluated in the
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1980s as a potential treatment of major depressive disorder (MDD)
in adults, development in depression was abandoned due to lack of
efficacy.10
Atomoxetine was the first nonstimulant medication approved
by the FDA for the treatment of ADHD based on a series of doubleblind, randomized controlled trials (RCTs) in children ≥6 years of
age, adolescents, and adults. In a large, comprehensive metaanalysis incorporating data from 24 RCTs in pediatric ADHD,
the effect size for total ADHD symptom improvement with ATX
was 0.64.11 Significant differences in ADHD symptoms vs placebo
were generally not noted until 4 weeks after treatment was initiated.11 Atomoxetine was associated with a bimodal response, that
is, 45% of patients were much improved at study end, while 40%
were considered nonresponders.11
Several RCTs have examined ATX efficacy and safety in children and/or adolescents with ADHD and specific comorbidities,
for example, oppositional defiant disorder (ODD), anxiety disorders, depressive disorders, tic disorders, and autism spectrum
disorders.12,13 Overall, comorbid disorders did not appear to compromise the efficacy of ATX in reducing ADHD symptoms. Atomoxetine not only did not exacerbate comorbidity symptoms in
RCTs,12,13 it appeared to have the potential for positive effects on
some comorbid symptoms, for example, reducing tic severity and
ODD symptoms in children and social anxiety disorder (SAD) in
children and adults.13 Improvements in comorbid ODD and anxiety symptoms correlated with improvements in ADHD symptoms.13 Atomoxetine had no significant benefit vs placebo in
adults with SAD without comorbid ADHD,14 suggesting that
previously observed benefits of ATX on comorbid anxiety were
mediated by the drug’s effects on ADHD.15 Despite the expected
improvements in ADHD symptoms, ATX effects on depressive
symptoms were no different vs placebo in children and adults with
comorbid MDD.13
The most common adverse events (AEs) of ATX in pediatric
ADHD RCTs were gastrointestinal symptoms (vomiting, abdominal pain, nausea, and diarrhea), nervous system symptoms (dizziness, headache, somnolence, sedation, and drowsiness), fatigue,
and anorexia.11 In adults, the most common AEs were constipation, dry mouth, nausea, decreased appetite, dizziness, erectile
dysfunction, and urinary hesitation.16 Safety concerns cited in
ATX prescribing information include a boxed warning about suicidal ideation in children and adolescents (risk ratio, ATX vs
placebo, 2.9217), as well as warnings about severe liver injury and
serious cardiovascular events.16 Cardiovascular effects of ATX
include increases in blood pressure (BP) and heart rate (HR). A
comprehensive safety review by the manufacturer found clinically
significant increases in HR (≥20 beats per minute [bpm]) and/or
BP (≥15-20 mm Hg) in 8% to 12% of children and adolescents.18
Atomoxetine is contraindicated in individuals with severe cardiovascular disorders and should be avoided in children or adolescents
with known serious cardiac problems.16

Dasotraline
Dasotraline (Sunovion) is considered a dual reuptake inhibitor
based on its preferential inhibition of dopamine transporters
(DAT) and NET and weaker inhibition of serotonin transporters
(SERT).*20 Like ATX, development of dasotraline in MDD in adults
was suspended due to lack of efficacy.21,22 Dasotraline dosed
*

Some sources have identified dasotraline as a triple reuptake inhibitor.19
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Figure 1. Molecular structure of currently approved and pipeline nonstimulant medications for attention-deficit/hyperactivity disorder.

q.d. was subsequently evaluated in a series of RCTs in adults and
children with ADHD, starting with a proof-of-concept Phase
2 study in adults treated with 4 mg or 8 mg (estimated DAT
receptor occupancy, 56% and 71%, respectively).23 Only 8 mg
dasotraline was superior to placebo (effect size, 0.41) in improving
total ADHD symptoms but was not well tolerated (discontinuation
due to AEs, 28%) in this exploratory study. Subsequent Phase
3 RCTs in ADHD evaluated 2 to 6 mg dasotraline.
In children and adolescents with ADHD, 4 mg dasotraline was
significantly superior to placebo in two RCTs, with an effect size of
0.85 in methylphenidate-responsive patients in a 2-week laboratory
classroom study24 and 0.48 in a 6-week fixed-dose study.25 In the fixeddose study, superiority of dasotraline over placebo emerged within the
first week. The lower dose of 2 mg dasotraline was not significantly
superior to placebo,25 while evaluation of 6 mg was terminated due to
unexpected neuropsychiatric AEs, including hallucinations.24 In a
Phase 3 study in adults, improvement with 4 mg dasotraline failed to
show a significant difference vs placebo in improving total ADHD
symptoms while the difference with 6 mg dasotraline trended toward
significance.26 In a posthoc analysis of pooled data from the two RCTs
in adults, improvements in ADHD symptoms were significantly
greater with dasotraline (4, 6, and 8 mg/day) vs placebo.26
The most common AEs with 2 and 4 mg dasotraline in children/
adolescents were insomnia, irritability, decreased appetite, and
decreased weight.25 Psychosis-related symptoms (hallucinations,
delusions) were reported in 5% of children receiving 4 mg and in
10% receiving 6 mg.24,25 Mean BP changes were minimal (≤3
mmHg).25 No clinically meaningful ECG changes were observed
in children. The most common AEs in adults were insomnia,
decreased appetite, and dry mouth.
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Results of the dasotraline-ADHD clinical development program
were reviewed by the FDA, which rejected approval pending additional efficacy and tolerability data.27 Dasotraline has also been
evaluated as a treatment of binge eating disorder in adults. As of
this writing, results of this clinical development program were
under review by the FDA.28
Centanafadine
Centanafadine (CTN, Otsuka) is a triple reuptake inhibitor (NET >
DAT > SERT) that is being developed as a sustained-release
(SR) formulation for b.i.d. dosing in ADHD.29,30 In a microdialysis
study in conscious rats, CTN increased extracellular NE, DA, and
serotonin (5-HT) concentrations from baseline by approximately
twofold in the prefrontal cortex; striatal extracellular DA was also
increased nearly twofold.29 A study in healthy volunteers supported dose-related brain occupancy of CTN-SR on NET, SERT,
and DAT.31 NET occupancy with CTN-SR was equivalent to that of
a typical dose of ATX; DAT occupancy was similar to that of a
typical long-acting methylphenidate dose. In light of the ability of
CTN-SR to increase DA, the drug’s abuse potential was evaluated
in an exploratory crossover-design study in healthy recreational
stimulant users, comparing an immediate-release (IR) formulation
of CTN with d-amphetamine and lisdexamfetamine.29,30 The subjective effects profile of CTN-IR was different from that of the
stimulants. With CTN-IR, aversive effects (dislike) during the
initial period when CTN exposure was rapidly increasing were
followed by increased “like” mean scores that were numerically
lower vs stimulants. Results were interpreted as indicators of low
abuse potential for CTN-SR.
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Table 1. Currently Approved and Pipeline Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD).
Pharmacologic Activity

ADHD Status

Dosing

Comments

Monoamine reuptake inhibitor
Atomoxetine

NET inhibitor

Approved for children
≥6 yrs and adults

q.d. or b.i.d.

Inconsistent, delayed (≥4 wks) treatment effect; bimodal response. Positive effects on
certain ADHD comorbidities (tics, ODD, and SAD symptoms, but not depressive
symptoms in comorbid MDD). Notable safety issues: suicidal ideation, liver toxicity,
and cardiovascular effects.

Dasotraline

DAT, NET inhibitor

FDA approval rejected
pending additional
data

q.d.

Significant treatment effect in children (4 mg) and adults (4, 6, 8 mg); early onset of effect
(1 wk). Dose-related psychosis symptoms (hallucinations, delusions) observed in
children. Most common AEs in children: insomnia, irritability, decreased appetite,
decreased weight. Most common AEs in adults: insomnia, decreased weight, dry
mouth.

Centanafadine sustained
release

NET, DAT, SERT inhibitor

Phase 3

b.i.d.

Limited clinical information. Significant treatment effect in Phase 2 studies in adults.
Low abuse potential (human abuse liability study).

OPC-64005

SERT, NET, DAT inhibitor

Phase 2

Not reported

No published data.

Clonidine extended release

α2A, α2B, α2C Agonist

Approved for children
≥6 yrs

b.i.d.

Guanfacine extended
release

α2A Agonist

Approved for children
≥6 yrs

q.d.

Repurposed antihypertensive agents. Primarily used as adjunct to stimulants. Early
onset of effect (wk 1 or 2). Positive effects on comorbid oppositionality/conduct
disorder and tics. Notable safety issues: cardiovascular effects (both agents), syncope
(guanfacine-XR) and abrupt discontinuation (clonidine-XR).

Vortioxetine

SERT inhibitor, 5-HT (5-HT1A, 5-HT1B, 5-HT3,
5-HT1D, 5-HT7) modulator

Phase 2 (approved for
MDD treatment)

q.d.

Repurposed antidepressant shown to improve cognitive processing speed in depressed
individuals. No clear efficacy signal (ADHD symptom reduction) in Phase 2 study in
adults with ADHD. No additional RCTs in ADHD underway.

Mazindol controlled
release

SERT, DAT, NET inhibitor, 5-HT (5-HT1A,
5-HT7), muscarinic, histamine H1,
μ-opioid, orexin-2 modulator

Phase 2

q.d.

Repurposed obesity treatment (Schedule IV). Significant treatment effect in Phase 2
study in adults with ADHD; early onset of effect (1 wk). Most common AEs: dry mouth,
nausea, fatigue, increased HR, decreased appetite, constipation. HR and BP
increased.

Viloxazine extendedrelease

NET inhibitor (weak), 5-HT (5-HT2C, 5-HT2B,
5-HT7), α1B and β2 modulator

Completed Phase 3
trials in pediatric
subjects with ADHD

q.d.

Repurposed antidepressant. Significant treatment effect in Phase 3 studies in children
and adolescents with ADHD; early onset of effect (1 wk). The most common
treatment-related AEs in the Phase 3 trials of SPN-812 (≥5% incidence) were
somnolence, headache, decreased appetite, fatigue, nausea, and upper abdominal
pain. No significant adverse cardiovascular effects.

Receptor modulator

Multimodal Agents

A. J. Cutler et al.

Abbreviations: AEs, adverse events; BP, blood pressure; DAT, dopamine transporters; HR, heart rate; MDD, major depressive disorder; NET, norepinephrine transporters; ODD, oppositional defiant disorder; SAD, social anxiety disorder; SERT, serotonin
transporters.
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Results of two Phase 2 studies have been published.30 In a pilot,
single-blind, flexible-dose (target dose, 500 mg/day), 4-week study
in adults with ADHD (N = 41), CTN-SR was associated with
significant reductions in ADHD symptoms vs baseline.30 A Phase
2b double-blind, crossover study (3-week treatment period; 1-week
washout) in 85 adults compared CTN-SR (target dose, 400–800
mg/day) and placebo. CTN-SR was significantly superior to placebo (effect size, 0.66).30 The most frequently reported treatmentrelated AEs were decreased appetite (24%), headache (23%), and
nausea (20%); 10% of subjects discontinued CTN-SR due to AEs.
Clinically significant ECG changes were not observed.
Two recently completed Phase 3 double-blind RCTs found
significant differences favoring 200 (100 mg b.i.d.) and 400 mg/
day (200 mg b.i.d.) CTN-SR over placebo in reducing ADHD
symptoms after 6 weeks of treatment in adults.32 The most common AEs occurring more frequently with CTN-SR vs placebo were
decreased appetite, headache, nausea, dry mouth, upper respiratory
tract infection, and diarrhea. The incidence of individual AEs did
not exceed 7%.32
OPC-64005
OPC-64005 (Otsuka) is a triple reuptake (SERT, NET, and DAT)
inhibitor.33 A Phase 2 flexible-dose study in adults with ADHD
compared OPC-64005 (titrated up to 30 mg/day) with placebo and
ATX (titrated up to 80 mg/day).34 Study results have not been
published.

Receptor Modulators
Extended-release formulations of the α2 adrenoreceptor agonists
guanfacine and clonidine are the only FDA-approved ADHD
therapies that have pharmacologic activities seemingly limited to
receptor modulation. Guanfacine appears to be selective for postsynaptic α2A receptors; clonidine has higher affinity for presynaptic
α2A, α2B, and α2C receptors than for postsynaptic α2A receptors.35
Although modulators of other receptors [eg, nicotinic acid, histamine, gamma-aminobutyric acid (GABA), 5-HT, adenosine A2A]
are of growing interest for their potential utility in treating ADHD,
clinical trials of these receptor modulators have so far produced
mixed results.36 None have advanced to Phase 3 trials in patients
with ADHD and are therefore unlikely to be clinically available for
several years, if at all.
Clonidine-XR (Kapvay®, Shionogi) and guanfacine-XR
(Intuniv®, Shire) were approved by the FDA for use not only as
monotherapy in children and adolescents (6–17 years old) with
ADHD but also as adjuncts to stimulants, which is their primary
use in clinical practice.37 Clonidine-XR is dosed b.i.d.; guanfacineXR is dosed q.d. In pivotal RCTs of clonidine-XR and guanfacineXR as monotherapy in youth with ADHD, effect sizes ranged from
0.43 to 0.86.38,39 Pooled effect sizes were not significantly different
for the two drugs.40 In fixed-dose clonidine-XR and guanfacine-XR
monotherapy studies, improvements in ADHD symptoms were
significantly greater vs placebo by week 1 or 2, with ADHD
symptoms typically improving further over the duration of the
8- and 9-week studies.38,41,42
Several RCTs of α2-agonist efficacy in ADHD also assessed
effects on scores for oppositional behavior and conduct problems
in children with or without comorbid ODD or CD. Based on a
meta-analysis, evidence was weak that the small effect of clonidine
(clonidine-IR and clonidine-XR combined) on oppositionality/
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conduct scores was clinically important.43 Evidence was somewhat stronger for positive effects of guanfacine-XR on oppositional behavior scores.43,44 A meta-analysis of α2-agonist RCTs
in patients with chronic tic disorders with or without ADHD
demonstrated a medium-to-large effect of α2 agonists (clonidineIR) in studies enrolling patients with tics and ADHD vs no
significant benefit in trials excluding patients with ADHD, suggesting a potential benefit in youth with ADHD and comorbid tic
disorders.45
The more common AEs associated with clonidine-XR and
guanfacine-XR are sedation/somnolence, fatigue, and gastrointestinal symptoms (nausea, abdominal pain). Consistent with the
therapeutic use of α2-agonists as antihypertensives, clonidine-XR
and guanfacine-XR can cause dose-related decreases in BP and
HR. A small but statistically significant prolongation of QTcF
interval was observed with guanfacine-XR vs placebo, although
guanfacine-XR does not appear to interfere with cardiac repolarization associated with proarrhythmic drugs.40,46 Safety concerns
about the cardiovascular effects are reflected in prescribing information, that is, clonidine-XR and guanfacine-XR should be used
with caution in patients at risk of hypotension, bradycardia, and, in
the case of guanfacine-XR, syncope.46,47 Heart rate and BP should
be monitored before and after initiating therapy with these agents,
while patients should avoid becoming dehydrated or overheated.
Prescribing information for clonidine-XR also warns about the risk
of abrupt discontinuation and the risk of allergic reactions in
patients with a history of allergic reactions, including contact
sensitization, with transdermal clonidine.47

Multimodal Agents
Multimodal agents are defined here as drugs that combine transporter (eg, NET, SERT, and DAT) modulation/inhibition with
receptor modulation (agonist and/or antagonist) activity. Several
such agents are being evaluated as potential ADHD treatments.
Vortioxetine
Vortioxetine (VORT, Trintellix®, Lundbeck, and Takeda) is
approved for the treatment of MDD in adults and has been suggested to improve cognitive processing speed in depressed individuals. It is a SERT inhibitor, agonist of 5-HT1A, partial agonist of
5-HT1B, and antagonist of 5-HT3, 5-HT1D, and 5-HT7.48 A Phase
2 proof-of-concept RCT of 10 or 20 mg/day q.d. in adults with
ADHD failed to detect a significant difference of VORT vs placebo
in improving total ADHD symptoms, although it was significantly
superior in reducing patient-rated functional impairment due to
ADHD.49 A post hoc analysis that excluded nonadherent patients
(32%) resulted in more pronounced changes from baseline in total
ADHD symptom scores for both VORT doses; similar patterns
were observed in other parameters. The AE profile in this exploratory study was consistent with the known profile of VORT, with
the most common AE being nausea. No additional studies of
VORT in ADHD are currently underway.
Mazindol
Immediate-release mazindol (MZD-IR) was marketed for the
short-term treatment of obesity in adults but was withdrawn from
the market for commercial reasons in the early 2000s.50 As an IR
formulation, mazindol is historically considered a weak stimulant
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(CIV) due to a lower potential for abuse and addiction vs the
classical CII stimulants. In more contemporary studies, MZD
displays multimodal pharmacologic activities that include NET,
DAT, and SERT inhibition (relative affinity, 100:12:2),51 as well as
modulation of serotonin (5-HT1A, 5-HT7), muscarinic, histamine
H1, μ-opioid, and orexin-2 receptors.50
In a pilot, 1-week, open-label study in children with ADHD
(N = 21) and MZD-IR (1 mg q.d.) was associated with significant
improvement in ADHD scores.52 Almost all patients (19/21)
reported ≥1 AE. The most common AEs were decreased appetite
(severe in four patients), drowsiness, intestinal distension, and
upper abdominal pain; insomnia was not reported. In a Phase
2 flexible-dose, 6-week RCT in adults with ADHD, mazindol
controlled-release (MZD-CR, Nolazol®, NLS Pharmaceutics) was
associated with significantly greater improvements in ADHD
scores vs placebo (effect size, 1.09).50 The proportion of patients
with excellent response (≥50% change from baseline) at 6 weeks
was 55% vs 16%. A significant difference favoring MZD-CR was
observed at the end of week 1. As expected of an agent previously
marketed for short-term weight loss, weight was decreased as early
as week 1; mean weight loss was 1.7 kg after 6 weeks. The most
common AEs were dry mouth, nausea, fatigue, increased HR,
decreased appetite, and constipation. Mean increases of ~3 to 6
mmHg in diastolic and systolic BP (DBP and SBP) and ~7 to
11 bpm in HR were observed. Phase 3 RCTs in ADHD are
planned.53
Viloxazine
Viloxazine as an immediate-release formulation was first marketed
as an antidepressant in Europe for more than two decades before
being discontinued for commercial reasons. Antidepressant efficacy was established in multiple double-blind RCTs in adults with
depressive disorders with/without comorbid anxiety.54 Conducted
in the 1970s, these RCTs used tricyclic antidepressants (TCAs) as
the active control. In these studies, viloxazine immediate-release
(150–300 mg/day) and TCAs improved symptoms of depression
and comorbid symptoms such as anxiety.54,55 Significant improvements in depression scores were generally noted within the first
week of treatment with viloxazine immediate-release, indicating
an early onset of effect.54
The tolerability/safety profile of viloxazine immediate-release
that emerged during more than two decades of use in adults was
relatively benign for the therapeutic class. Compared with TCAs,
viloxazine immediate-release had a better tolerability/safety
profile, particularly with regard to sedation and anticholinergic
effects.53,54,55 Viloxazine immediate-release was associated with
fewer cardiovascular effects,56 including minimal detrimental
effects on BP.57 Viloxazine immediate-release was not associated
with dose-related depression of cardiac contractility in healthy
volunteers; symptoms did not include cardiac complications in
postmarketing reports of viloxazine immediate-release overdose.58
The therapeutic effects of viloxazine in depression were historically attributed to NET inhibition. Early preclinical studies, however, found a more complex pharmacologic profile involving the
potentiation of 5-HT without inhibiting SERT.54 In contemporary
preclinical studies using more sophisticated methods, extracellular
5-HT concentrations in the prefrontal cortex were increased
>5-fold by viloxazine by an unknown mechanism that likely
involves 5-HT receptor modulation.59 Prefrontal cortex dopamine
and norepinephrine concentrations were also increased >5-fold.
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Monoamine transmitter concentrations were minimally increased
in the nucleus accumbens. In addition to moderate NET inhibition,
viloxazine exhibited agonistic activity at 5-HT2C, antagonistic
activity at 5-HT2B, and weak antagonistic activity at 5-HT7, α1B,
and β2 receptors.59
Double-blind, placebo-controlled RCTs have consistently demonstrated a treatment effect significantly favoring viloxazine over
placebo in reducing ADHD symptoms, starting with a Phase 2a
proof-of-principle study of viloxazine immediate-release (100 mg t.
i.d) in adults.60 A Phase 2b dose-ranging RCT in children found
that viloxazine extended-release (SPN-812, Supernus Pharmaceuticals) at dosages of 200, 300, and 400 mg dosed q.d. was significantly superior to placebo in improving ADHD symptoms, with
effect sizes of 0.547, 0.596, and 0.623, respectively.61 SPN-812 was
subsequently evaluated in four Phase 3 double-blind, placebocontrolled, fixed-dose RCTs in children and adolescents with
ADHD. Two studies (NCT03247530562; NCT0324754363) were
conducted in children 6 to 11 years of age (100 mg, 200 mg, 400
mg); two studies (NCT0324751764; NCT0324755665) were in adolescents 12 to17 years of age (200 mg, 400 mg, 600 mg). Depending
on target dose, SPN-812 was titrated over 1 to 3 weeks (starting
dose: 100 mg in children; 200 mg in adolescents); the target dose
was maintained for at least 5 weeks. Across the four studies
(N=1354, intent-to-treat population), subjects were treated with
SPN-812 (100 mg, n = 147; 200 mg, n = 359; 400 mg, n = 299;
600 mg, n = 97) or placebo (n = 456). In three Phase 3 studies,
subjects consistently displayed greater ADHD symptom improvement with SPN-812 vs placebo. Differences vs placebo in the
change from baseline in ADHD-RS-5 Total score at end of study
(EOS) were statistically significant with once-daily 100 and 200 mg
SPN-812 in one Phase 3 trial conducted in children, and with
200 mg and 400 mg SPN-812 in two Phase 3 trials – one conducted
in children and one conducted in adolescents. In the fourth study,
the primary endpoint was not met; one of the two (400- and
600-mg/day) doses of SPN-812 (600-mg/day) did not separate
from placebo. This was possibly due to a higher placebo response
observed in this study, which may have confounded the treatment
response. For 100-400 mg SPN-812, symptom improvement was
observed as early as the first week of treatment. ADHD symptoms
steadily improved over the entire course of double-blind treatment.
Core ADHD symptom domains—inattention and hyperactivity/
impulsivity—were improved to similar degrees. Parent-assessed
outcomes generally mirrored those of investigators. Parents perceived greater ADHD symptom improvement, greater reduction of
functional impairment, and less stress with SPN-812 treatment vs
placebo. The proportion of patients in the Phase 3 studies with 50%
or greater improvement in ADHD-RS-5 Total score compared to
baseline (50% responder rate) and proportion of patients “much
improved” or “very much improved” per the CGI-I scale were also
assessed. The 50% responder rate ranged from 34.2% to 48.2% at
EOS; 45.0% to 60.6% of patients were categorized as “much” or
“very much improved” per CGI-I scale at EOS. SPN-812 was well
tolerated. Discontinuation rate due to treatment-related AEs was
<5% for SPN-812 treatment groups within each study. The most
common treatment-related AEs in the Phase 3 trials of SPN-812
(≥5% incidence) were somnolence, headache, decreased appetite,
fatigue, nausea, and upper abdominal pain. The treatment-related
AEs usually emerged within the first month of treatment and most
resolved with continued treatment. The most common AEs leading
to SPN-812 discontinuation (≥2 subjects) were somnolence (n = 7),
fatigue (n = 3), nausea (n = 3), tachycardia (n = 3), decreased appetite (n = 2), and headache (n = 2).
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A recently published study evaluated the effect of SPN-812 on
QTc interval in healthy adult subjects. The study demonstrated
that supratherapeutic (1800 mg q.d.) dose of SPN-812 had no
significant effect on cardiac repolarization or other ECG parameters, suggesting that it does not pose a risk of cardiac arrhythmias
in healthy adults.66 Cardiac AEs in SPN-812 Phase 3 study populations were infrequent, with only two incidences of tachycardia
and one incidence of ECG T-wave inversion leading to discontinuation and considered related or possibly related to treatment
across all four studies.62-65 During intensive monitoring of suicidality, suicidal ideation and suicidal behavior were infrequent
occurrences, with no incidence of suicidal ideation considered
related to treatment and only one incidence of suicidal attempt in
an SPN-812 treatment group considered possibly related to treatment.62-65
The Phase 3 clinical program in pediatric population has been
completed.67 Results from an ongoing Phase 3 study in adults with
ADHD (NCT04016779) are expected in 2021.68

Why More Options to Schedule II Stimulants Are Needed
We propose several reasons that all clinicians should develop a
deeper appreciation of nonstimulants in the treatment of ADHD in
both children/adolescents and adults and the need for a broader
array of options. First, while stimulants are highly effective in
reducing ADHD symptoms, a substantial number of patients either
fail to respond and/or have unacceptable side effects when treated
with stimulants. In such scenarios, the use of nonstimulants is both
appropriate and well supported by various treatment guidelines.
Second, stimulants often are less than ideal treatment options in
ADHD patients with commonly occurring symptoms such as
insomnia, poor appetite, subsyndromic anxiety or depression,
and failure to thrive. Nonstimulants are treatment options in such
patients—either as monotherapy or as cotherapy with stimulants.
In addition, continuous, even coverage of ADHD symptoms is
often a clinical necessity. However, even the longest acting stimulant formulation often fails to provide adequate duration of coverage. In such situations, nonstimulants can be useful—again, either
as monotherapy or combination therapy. Finally, the potential
euphorigenic effects and abuse liability that make CII stimulants
medications may negatively impact acceptance and adherence due
to complex procedures in renewing a CII medication as well as
misinformation, biases, or uncertainty about the use of stimulants
to treat ADHD.
With more than 30 CII stimulant preparations commercially
available, the field of ADHD is currently limited to just three FDAapproved nonstimulant agents that either modulate the norepinephrine reuptake pump or stimulate norepinephrine α2 receptors.69 Only one (ATX) is approved for use in adults. Atomoxetine
has inconsistent and delayed efficacy, with a bimodal distribution
of response, and carries significant warnings involving suicidal
ideation, liver injury, and cardiovascular effects. The use of
clonidine-XR and guanfacine-XR is limited by sedation and somnolence, particularly when used as monotherapy, while safety
concerns include cardiovascular warnings, such as hypotension,
bradycardia, and the risk of syncope in the case of guanfacine-XR.
In light of the complex neurobiology of ADHD, novel nonstimulant options are needed that may be more suited to the diverse
needs of pediatric and adult patients with ADHD and its associated
comorbidities, including patients with comorbid psychiatric
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disorders such as depression or anxiety. Several promising alternatives to CII stimulants with different mechanisms of action are in
clinical development, with one such agent currently being reviewed
by the FDA. These new agents may be of benefit in ADHD patients
in whom treatment has been limited by comorbidities that make
stimulants inappropriate as first-line therapy or have inadequate
response or side effects with currently available treatment options.
Finally, the concept of ADHD symptom remission is gathering
more traction in both psychiatry and pediatrics. If clinicians are to
accept this as a “gold standard” for all patients with ADHD, then a
deeper appreciation of the strengths and weaknesses of both simulants and nonstimulants is necessary.

Conclusions
ADHD medication development has focused on engineering novel
systems for CII stimulants—liquids, capsules, sprinkles, chewables,
and prodrugs—that have different pharmacokinetics due to different stimulant formulation release profiles. In contrast, current
development of novel medications is exploring new molecular
entities with different structures and molecular targets. These
molecules differ markedly from the older agents by targeting
reuptake inhibition of multiple monoamines, modulation of receptors other than noradrenergic α2 neurotransmitter receptors, and
multimodal agents that combine reuptake inhibition with direct
receptor modulation. Interest in these new agents include their
potential for rapid onset of action and a more favorable safety
profile. Hopefully, future research will also assess each of these
agent’s ability to beneficially influence the diverse clinical needs
and comorbidities associated with ADHD, including their effects
on mood, sleep, anxiety, combined with the potential for lower
abuse liability.
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